B+L Tampa

Quote

anonymous

Guest
"This morning (7/22), Valeant announced that it has received a Complete Response Letter (CRL) from the FDA regarding its glaucoma product candidate latanoprostene bunod. The CRL sites concerns regarding manufacturing deficiencies pertaining to an inspection of a Bausch & Lomb manufacturing facility in Tampa, Florida. The CRL was unexpected and we had included latanoprostene bunod in our model with peak sales of $150 million in 2020." WF Analyst
 






Great Job in 2016 Tampa!
First you fail to properly package product and now FDA denies approval based on GMP concerns..
Sounds like it's time again to promote some more incompetence!!
 






anonymous said:
Great Job in 2016 Tampa!
First you fail to properly package product and now FDA denies approval based on GMP concerns..
Sounds like it's time again to promote some more incompetence!!
Click to expand...

The PRNewswire statement said there were deficiencies-- not one deficiency, but more than one. So what else besides a packaging problem?

Kristy Marks said they are working as quickly as possible to expedite all corrections as necessary. What kind of corrections? And who gets the blame?
 


















When Pearson and his mcKinsey henchmen walked in on day one they fired all the people who knew how to control this stuff and were warned by many in B+L that this approach would come back and haunt them one day...and here we are...just interesting that Pearson got canned even before all this started to come back on him...and mcKinsey are still counting their bonus for such inept approach..
.
 


















anonymous said:
When Pearson and his mcKinsey henchmen walked in on day one they fired all the people who knew how to control this stuff and were warned by many in B+L that this approach would come back and haunt them one day...and here we are...just interesting that Pearson got canned even before all this started to come back on him...and mcKinsey are still counting their bonus for such inept approach..
.
Click to expand...
 






interesting to see Pearson and McKinsey mentioned in the same sentence. Word is that they are back to help tackle Pearson's mountain of debt. Working to take 1.3 billion dollars out of the manufacturing and distribution operations of contact lens
 






anonymous said:
interesting to see Pearson and McKinsey mentioned in the same sentence. Word is that they are back to help tackle Pearson's mountain of debt. Working to take 1.3 billion dollars out of the manufacturing and distribution operations of contact lens
Click to expand...
Yup. Like moths to a flame. Valeant brought McKinsey back. Cost cutting began under Saunders. There were several waves of job cuts under Warberg. Remember broadening and flattening? That is what Valeant had to start with and they still indiscriminately cut x% right from the start.

McKinsey is beyond over rated. They will pick a cost cutting model from their playbook. Then come in to do studies and interviews to justify their preset recommendations. They already pushed the decentralized model and that didn't work. They will see that Papa likes a more global company and will recommend consolidation and economies of scale. It doesn't matter what model McKinsey chooses, it will end with job cuts.
 






Watch out for legal case pending against McKinsey. Their indemnity insurance is broad and deep and has enough reserves to cover a multi billion claim from Papa. Remember Papa will not go down in flames for a problem he did not create. He is on fire right now with huge debt repayment demands - so limited time to act.

Their inept and amateur approach to consolidation is starting to emerge. This may lead to their total demise.
 












anonymous said:
When Pearson and his mcKinsey henchmen walked in on day one they fired all the people who knew how to control this stuff and were warned by many in B+L that this approach would come back and haunt them one day...and here we are...just interesting that Pearson got canned even before all this started to come back on him...and mcKinsey are still counting their bonus for such inept approach..
.
Click to expand...
 






Top Bottom
Back
Quote